Funding of £5m will create new jobs in Norfolk
Thirty new laboratories and offices for 300 research scientists are to be built in Norfolk, UK
The new development will be based at Norwich Science Park and provide facilities for start-up and expanding businesses.
BBSRC will provide £500,000 as well as the land and buildings to host the new facilities, with £1.4m coming from the East of England Development Agency (EEDA), £1m from the Greater Norwich Development Partnership (GNDP), £500,000 from NRP partner the University of East Anglia (UEA), and the remainder from other NRP partners.
The new facilities, to be opened in July, will be managed by a new joint venture company called Colney Innovations (CIL).
David Parfrey, BBSRC director of finance and director of CIL, said: "The research carried out by the 2,000 scientists already working at Norwich Science Park is world-class and it makes absolute sense to create a facility on this site where the results of such research can be taken through to applications."
Prof Douglas Kell, chief executive of BBSRC, added: "The Norwich Research Park is home to three world-class BBSRC institutes: the John Innes Centre, the Institute of Food Research and The Genome Analysis Centre. This new facility will play a key role in helping our scientists, and others, to translate their excellent science into products to benefit the economy and people of the UK."
You may also like
Trending Articles
You may also like
Finance
hVIVO’s CRS secures more than £5m in early-phase clinical trial contracts to strengthen 2026 pipeline
hVIVO’s German subsidiary CRS has signed more than £5 million in early-phase clinical trial contracts across cardiometabolic, dermatology, infectious disease, renal and oncology, bolstering its 2026 orderbook and highlighting the growing cross-selling benefits across the Group
Manufacturing
Moderna invests $140m to onshore drug product manufacturing and complete US end-to-end mRNA network
Moderna is expanding its Norwood, Massachusetts site to bring drug product manufacturing in-house, creating hundreds of biomanufacturing jobs and establishing full domestic, end-to-end production for its mRNA vaccines and therapeutics by 2027
Manufacturing
GEA to showcase Rockwell Automation-Compatible GEA kytero 2000 Single-Use Separator at Automation Fair 2025
As a gold-level OEM member of the Rockwell PartnerNetwork™, GEA is strengthening its collaboration with Rockwell by offering full compatibility between the kytero® 2000 and Rockwell’s latest hardware and software suite
Research & Development
OSE Immunotherapeutics gets positive IDMC recommendation to continue Phase III trial of Tedopi for lung cancer
The Independent Data Monitoring Committee has endorsed the ongoing pivotal Phase III ARTEMIA study evaluating Tedopi in HLA-A2–positive metastatic non-small cell lung cancer